E. Zeynep Erson Omay

E. Zeynep Erson Omay


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2017 in Genome Medicine
Verified
Journal Article
Open access
PDF file
EOE. Zeynep Erson Omay
E. Zeynep Erson Omay
OHOctavian Henegariu
Octavian Henegariu
SOSacit Bulent Omay
Sacit Bulent Omay
AHAkdes Serin Harmancı
Akdes Serin Harmancı
MYMark W. Youngblood
Mark W. Youngblood
MGMurat Günel
Murat Günel
Glioblastoma multiforme (GBM) constitutes nearly half of all malignant brain tumors and has a median survival of 15 months. The standard treatment for these lesions includes maximal resection, radiotherapy, and chemotherapy; however, individual tumors display immense variability in their response to these approaches. Genomic techniques such as whole-exome sequencing (WES) provide an opportunity to understand the molecular basis of this variability. Here, we report WES-guided treatment of a patient with a primary GBM and two subsequent recurrences, demonstrating the dynamic nature of treatment-induced molecular changes and their implications for clinical decision-making. We also analyze the Yale-Glioma cohort, composed of 110 whole exome- or whole genome-sequenced tumor-normal pairs, to assess the frequency of genomic events found in the presented case. Our longitudinal analysis revealed how the genomic profile evolved under the pressure of therapy. Specifically targeted approaches eradicated treatment-sensitive clones while enriching for resistant ones, generated due to chromothripsis, which we show to be a frequent event in GBMs based on our extended analysis of 110 gliomas in the Yale-Glioma cohort. Despite chromothripsis and the later acquired mismatch-repair deficiency, genomics-guided personalized treatment extended survival to over 5 years. Interestingly, the case displayed a favorable response to immune checkpoint inhibition after acquiring mismatch repair deficiency. Our study demonstrates the importance of longitudinal genomic profiling to adjust to the dynamic nature of treatment-induced molecular changes to improve the outcomes of precision therapies.

1 January 2025 in Nature
Verified
Journal Article
Open access
PDF file
CZCe Zhang
Ce Zhang
DLDan Liang
Dan Liang
AEA. Gulhan Ercan-Sencicek
A. Gulhan Ercan-Sencicek
ABAybike S. Bulut
Aybike S. Bulut
JCJoelly Cortes
Joelly Cortes
KBKaya Bilguvar
Kaya Bilguvar
Cerebral cortex development in humans is a highly complex and orchestrated process that is under tight genetic regulation. Rare mutations that alter gene expression or function can disrupt the structure of the cerebral cortex, resulting in a range of neurological conditions1. Lissencephaly (‘smooth brain’) spectrum disorders comprise a group of rare, genetically heterogeneous congenital brain malformations commonly associated with epilepsy and intellectual disability2. However, the molecular mechanisms underlying disease pathogenesis remain unknown. Here we establish hypoactivity of the mTOR pathway as a clinically relevant molecular mechanism in lissencephaly spectrum disorders. We characterized two types of cerebral organoid derived from individuals with genetically distinct lissencephalies with a recessive mutation in p53-induced death domain protein 1 (PIDD1) or a heterozygous chromosome 17p13.3 microdeletion leading to Miller–Dieker lissencephaly syndrome (MDLS). PIDD1-mutant organoids and MDLS organoids recapitulated the thickened cortex typical of human lissencephaly and demonstrated dysregulation of protein translation, metabolism and the mTOR pathway. A brain-selective activator of mTOR complex 1 prevented and reversed cellular and molecular defects in the lissencephaly organoids. Our findings show that a converging molecular mechanism contributes to two genetically distinct lissencephaly spectrum disorders.

1 May 2023 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
ADAlper Dincer
Alper Dincer
MJMuhammad I Jalal
Muhammad I Jalal
TGTrisha P Gupte
Trisha P Gupte
SVShaurey Vetsa
Shaurey Vetsa
SVSagar Vasandani
Sagar Vasandani
JMJennifer Moliterno
Jennifer Moliterno
Meningiomas are the most common central nervous system tumors. Although these tumors are extra-axial, a relatively high proportion (10%–50%) of meningioma patients have seizures that can substantially impact the quality of life. Meningiomas are believed to cause seizures by inducing cortical hyperexcitability that results from mass effect and cortical irritation, brain invasion, or peritumoral brain edema. In general, meningiomas that are associated with seizures have aggressive features, with risk factors including atypical histology, brain invasion, and higher tumor grade. Somatic NF2 mutated meningiomas are associated with preoperative seizures, but the effect of the driver mutation is mediated through atypical features. While surgical resection is effective in controlling seizures in most patients with meningioma-related epilepsy, a history of seizures and uncontrolled seizures prior to surgery is the most significant predisposing factor for persistent postoperative seizures. Subtotal resection (STR) and relatively larger residual tumor volume are positive predictors of postoperative seizures. Other factors, including higher WHO grade, peritumoral brain edema, and brain invasion, are inconsistently associated with postoperative seizures, suggesting they might be crucial in the development of an epileptogenic focus, but do not appear to play a substantial role after seizure activity has been established. Herein, we review and summarize the current literature surrounding meningioma-related epilepsy and underscore the interaction of multiple factors that relate to seizures in patients with meningioma.

22 January 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
LKLeon D. Kaulen
Leon D. Kaulen
EOE. Zeynep Erson Omay
E. Zeynep Erson Omay
OHOctavian Henegariu
Octavian Henegariu
PKPhilipp Karschnia
Philipp Karschnia
AHAnita Huttner
Anita Huttner
JBJoachim M. Baehring
Joachim M. Baehring

14 May 2022 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
EOE. Zeynep Erson Omay
E. Zeynep Erson Omay
SVShaurey Vetsa
Shaurey Vetsa
SVSagar Vasandani
Sagar Vasandani
TBTanyeri Barak
Tanyeri Barak
ANArushii Nadar
Arushii Nadar
JMJennifer Moliterno
Jennifer Moliterno
Background: Multiple meningiomas (MMs) rarely occur sporadically. It is unclear whether each individual tumor in a single patient behaves similarly. Moreover, the molecular mechanisms underlying the formation of sporadic MMs and clonal formation etiology of these tumors are poorly understood. Methods: Patients with spatially separated MMs without prior radiation exposure or a family history who underwent surgical resection of at least two meningiomas were included. Unbiased, comprehensive next generation sequencing was performed, and relevant clinical data was analyzed. Results: Fifteen meningiomas and one dural specimen from six patients were included. The majority of tumors (12/15) were WHO Grade I; one patient had bilateral MMs, one of which was Grade II, while the other was Grade I. We found 11/15 of our cohort specimens were of NF2-loss subtype. Meningiomas from 5/6 patients had a monoclonal origin, with the tumor from the remaining patient showing evidence for independent clonal formation. We identified a novel case of non-NF2 mutant MM with monoclonal etiology. MMs due to a monoclonal origin did not always display a homogenous genomic profile, but rather exhibited heterogeneity due to branching evolution. Conclusions: Both NF2-loss and non-NF2 driven MMs can form due to monoclonal expansion and those tumors can acquire inter-tumoral heterogeneity through branched evolution. Grade I and II meningiomas can occur in the same patient. Thus, the molecular make-up and clinical behavior of one tumor in MMs, cannot reliably lend insight into that of the others and suggests the clinical management strategy for MMs should be tailored individually.

11 January 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
AKAdam J. Kundishora
Adam J. Kundishora
BRB.A. Benjamin Reeves
B.A. Benjamin Reeves
CNCarol Nelson‐Williams
Carol Nelson‐Williams
CHChristopher S. Hong
Christopher S. Hong
PGPallavi P. Gopal
Pallavi P. Gopal
EOE. Zeynep Erson Omay
E. Zeynep Erson Omay